Welcome to hitechpharm.com, the website of Hi-Tech Pharmacal Co., Inc.

I am proud to present to you Hi-Tech Pharmacal Co., Inc., a dynamic and growing company dedicated to developing and marketing high quality pharmaceutical products you can trust.

As a developer and manufacturer of liquid and semi solid dosage forms we are currently presented with enormous opportunities never before available to us - over $5 billion of branded liquid and semi-solid pharmaceutical products will lose patent protection over the next five years. These products include solutions for oral, otic and ophthalmic use, solutions for inhalation, suspensions, nasal sprays, as well as creams and ointments. Hi-Tech has the expertise necessary to develop and manufacture these drugs, including those products that require sterile manufacturing.

Hi-Tech's goal is to become a leading manufacturer of liquid and semi-solid dosage pharmaceutical products in the US. We believe that this ambitious goal will be accomplished through investing in R&D, building a dedicated and experienced management team and strengthening ties with our customers and pharmacists.

We will also continue to strengthen our presence in the branded pharmaceuticals marketplace with our OTC and prescription products targeting the diabetic consumer.

We thank you for your interest in Hi-Tech Pharmacal, our products and business strategies.

Sincerely,

David Seltzer
President & Chief Executive Officer

About Hi-Tech

Hi-Tech Pharmacal Co., Inc . ( NASDAQ: HITK ) is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription and OTC products for the general healthcare industry.

• Specializes in liquid and semi-solid manufacturing; niche in sterile production
• Offers over 100 generic and branded products to approximately 100 customers
• Founded in 1982, NASDAQ IPO in1992
• Employs approximately 250, with headquarters and manufacturing facilities in Amityville, NY

MAJOR PRODUCTS AND CUSTOMERS

The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and manufactures a range of sterile ophthalmic, otic and inhalation products. Among its leading generic products are Albuterol Sulfate solution for inhalation, Albuterol Sulfate Syrup, Sulfamethoxazole/Trimethoprim suspension, Promethazine syrup, Prednisolone syrup, Amantadine HCL syrup, Brometane DX, Lactulose solution, Valproic Acid solution, Hydroxine Syrup, Urea 40% cream, lotion and gel.

Customers include leading

• Chains: CVS, Walgreens, RiteAid,
• Wholesalers: McKesson, AmeriSource Bergen, Cardinal,
• Managed care organizations: Novation, Premier
• Governmental agencies: FSS , VA

RESEARCH & DEVELOPMENT

Hi-Tech has 33 Abbreviated New Drug Application (ANDA) approvals to date; 11 products are currently under review with the FDA with a brand market value of approximately $1.6B. Products under review include sterile ophthalmic solutions, oral solutions and suspensions. In FY 2006, Hi-Tech's R&D spending was over $3.3mm. The Company has approximately twenty products in various stages of development. The program includes oral solutions and suspensions, sterile ophthalmic solutions, products for inhalation and nasal sprays, with addressable market of approximately $2 B.

FOCUS ON DIABETES

The Company's Health Care Products Division (HCP) develops and markets products helping people with diabetes live healthier lives. The diabetes marketplace presents enormous opportunities for the Company. There are 17 millions people with diabetes in the US , and 800,000 new cases are registered every year. HCP is widely viewed as the leader in the over the counter business targeting the diabetic consumer: the Diabetic Tussin ® line of products consistently ranks number one among sugar free cough & cold remedies. Company's fastest growing brand is the DiabetiDerm ® line lead by DiabetiDerm ® Foot Cream with L-Arginine. HCP plans to add new products to the line targeting specific dermatological and podiatric conditions in people with diabetes and expand its reach through an aggressive telemarketing campaign and through promotion directly to podiatrists and dermatologists.